Cardiology & Vascular Research

Cardiology & Vascular Research

Open Access
ISSN: 2639-8486
Case Report

Thrombolytics, Still the First Therapeutic Weapon Against Acute STSegment Elevation Myocardial Infarction

Authors: Benaim F Leonel, Fonseca Sebastian Raúl, Blanco Mailen, Cohen Arazi Hernan, Ferreyra Raúl.

DOI: 10.33425/2639-8486.1070


Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide, being coronary events the most common cause of CVD. In the case of an acute ST-segment elevation myocardial infarction, the conventional treatment involves the reperfusion of the culprit artery as soon as possible as angioplasty has replaced the thrombolysis therapy.

We present two patients with acute ST-segment elevation myocardial infarction. The first patient showed an STsegment elevation of the anterolateral wall, and the second one, in the inferolateral wall. In both cases we performed rapid reperfusion with thrombolytics (ischemic time less than 30 minutes), with good response.

The first patient showed a lesion in the subendocardial myocardium in the late gadolinium enhancement in cardiovascular magnetic resonance imaging.

Taking into account the time delays of patients-derivation and door-to-balloon time in developing countries, these cases reinforce the indication of thrombolytics as the treatment of choice.

View / Download PDF
Citation: Benaim F Leonel, Fonseca Sebastian Raúl, Blanco Mailen, et al. Thrombolytics, Still the First Therapeutic Weapon Against Acute STSegment Elevation Myocardial Infarction. 2020; 4(1). DOI: 10.33425/2639-8486.1070
Editor-in-Chief
Aris Lacis
Aris Lacis
Head of the Latvian State Cardiology Centre for Children | Head of the Clinic for Children Cardiology Latvia

View full editorial board →
Journal Metrics
Impact Factor 2.4*
Acceptance Rate 74.5%
Time to first decision 6-10 Days
Submission to acceptance 10-15 Days